The safety profile of bosentan (Tracleer®), an endothelin receptor antagonist approved for the treatment of pulmonary arterial hypertension (PAH), has been confirmed in a unique large-scale pan-European surveillance programme, according to a study undertaken by Marc Humbert (Antoine Beclere Hospital, Clamart, France) and his colleagues. [click link for full article]
(more...)